CureVac GmbH
Paul-Ehrlich-Str. 15
Tübingen
72076
Germany
Tel: 49-7071-92053-0
Fax: 49-7071-92053-11
Website: http://www.curevac.de/
117 articles with CureVac GmbH
-
CureVac Provides Supervisory Board Update
6/23/2021
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that Dr. Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board.
-
Please check out the biopharma industry's COVID-19 stories that are trending for June 22, 2021.
-
The new findings likely throw a wrench in the company's plans to deliver millions of much-needed vaccine doses to the European Union soon.
-
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
5/28/2021
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the independent Data Safety Monitoring Board has confirmed that the pivotal Phase 2b/3 study for CureVac's first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases.
-
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
-
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
5/13/2021
CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
-
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
-
CureVac to Participate in Upcoming Investor Conferences - Feb 18, 2021
2/18/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it will be participating in the following upcoming investor conferences
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
-
CureVac to Host Conference Call on COVID-19 Partnership Update on February 5, 2021
2/5/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, will host a conference call and webcast on , Friday February 5, 2021 at 4:00 p.m. CET / 10:00 a.m. EST.
-
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
-
GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines
2/3/2021
Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval
-
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
-
CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares
1/28/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the pricing of its follow-on public offering of 5,000,000 common shares at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
-
CureVac Announces Proposed Public Offering of Common Shares
1/25/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it intends to offer and sell in an underwritten public offering 5,000,000 common shares.
-
CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
1/11/2021
Data provided further evidence on immunogenicity and protective efficacy of CVnCoV Induction of robust antibody and T cell responses at lower dose than tested in Phase 3 trial Full lung protection of CVnCoV-vaccinated animals during SARS-CoV-2 challenge infection
-
Here’s a run-down of some of the most recent collaboration announcements this week.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.